Analysts expect Avalyn Pharma Inc. to report revenue of 0.00 for Q3 26, against a range of 0.00 to 0.00. The most recent reported quarter, Q2 26, came in at 0.00.
| Metric | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 |
|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | 0.00 | - | - | - | - |
| High Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Low Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consensus Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analysts expect Avalyn Pharma Inc. to report earnings per share of -0.76 for Q3 26, against a range of -0.83 to -0.69. The most recent reported quarter, Q2 26, came in at -0.98, a 36.1% miss against the -0.72 consensus.
| Metric | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -21.83 | -0.98 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -5.59 | -0.68 | -0.69 | -0.82 | -16.37 | 4.97 | 5.33 | 4.53 | -14.37 | 4.77 | ||||||||||
| Low Estimate | -6.69 | -0.76 | -0.83 | -0.88 | -18.17 | 4.09 | 4.43 | 4.03 | -17.05 | 4.47 | ||||||||||
| Consensus Estimate | -6.14 | -0.72 | -0.76 | -0.85 | -17.27 | 4.53 | 4.88 | 4.28 | -15.71 | 4.62 |
Pull Wall Street consensus for Avalyn Pharma Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=AVLN&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "AVLN", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=AVLN&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();